GlassScriptPhysician profile
Gordon David Luk
NPI 1003877432
$347.48
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $77.97 · 2021: $82.93 · 2022: $14.32 · 2023: $49.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $49.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $49.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $97.04 | 2019-2021 | |
| Pfizer INC. | $60.94 | 2019-2021 | |
| Ethicon US, LLC | $35.39 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.21 | 2021 | |
| Amgen INC. | $25.03 | 2023 | Amjevita, Avsola |
| Lilly USA, LLC | $24.55 | 2023 | |
| Janssen Biotech, INC. | $24.51 | 2021 | |
| Endogastric Solutions, INC | $23.98 | 2019 | |
| Qol Medical, LLC | $15.51 | 2019 | |
| Merck Sharp & Dohme LLC | $14.32 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$13,352.13 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gordon Luk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.